Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 May;84(5):1006-1012.
doi: 10.1111/bcp.13521. Epub 2018 Mar 1.

Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations

Affiliations
Comparative Study

Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations

Eden C Andrew et al. Br J Clin Pharmacol. 2018 May.

Abstract

Aims: Lipid formulations of amphotericin B, rather than conventional amphotericin (c-amB), are increasingly used despite limited data comparing these preparations in children. Data on the incidence of adverse effects with amphotericin B at standard doses are scarce. This study aimed to compare the adverse effects associated with standard doses of c-amB and liposomal amphotericin (l-amB) in children.

Methods: Children admitted to the Royal Children's Hospital Melbourne and treated with c-amB or l-amB between January 2010 and September 2013 were included. Clinical and laboratory data were retrospectively extracted from medical records to compare amphotericin-related infusion reactions, nephrotoxicity (glomerulotoxicity and tubulopathy) and hepatotoxicity.

Results: Seventy-six children received c-amB and 39 received l-amB. Standard drug administration (recommended dose and infusion time) occurred in 74% (56/76) of patients on c-amB and 85% (33/39) on l-amB. In these 89 children, infusion-related reactions were similar for both c-amB and l-amB (23% (13/56) vs. 9% (3/33); P = 0.15); none occurred in children aged <90 days. There was no difference in amphotericin-associated glomerulotoxicity (c-amB 14% (8/56) vs. l-amB 21% (7/33); P = 0.40) or in the median maximum potassium requirements (c-amB 3.1 vs. l-amB 2.3 mmol kg-1 d-1 ; P = 0.29). Hepatotoxicity occurred more frequently with l-amB than c-amB (83% (24/29) vs. 56% (20/36); P = 0.032).

Conclusions: When appropriately administered, l-amB was associated with more hepatotoxicity than c-amB, with no difference in infusion-related reactions or nephrotoxicity. Differences in adverse effects between the preparations is not as marked in children as reported in adults.

Keywords: Amphotericin-B; adverse effects; antifungal; liposomal; paediatric.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Dzierzanowska‐Fangrat K, Romanowska E, Gryniewicz‐Kwiatkowska O, Migdal M, Witulska K, Ryzko J, et al Candidaemia in a Polish tertiary paediatric hospital, 2000 to 2010. Mycoses 2014; 57: 105–109. - PubMed
    1. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55: 809–818. - PubMed
    1. Richardson M, Lass‐Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008; 14 (Suppl. 4): 5–24. - PubMed
    1. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013; 73: 919–934. - PubMed
    1. Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database of Syst Rev 2015; 11: CD010481. - PMC - PubMed

Publication types